{"id":537,"date":"2020-09-15T10:56:12","date_gmt":"2020-09-15T10:56:12","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=537"},"modified":"2020-09-15T10:56:12","modified_gmt":"2020-09-15T10:56:12","slug":"13-sep-2020-anakinra-tocilizumab-associated-with-improved-clinical-outcomes","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/13-sep-2020-anakinra-tocilizumab-associated-with-improved-clinical-outcomes\/","title":{"rendered":"(13 Sep 2020) Anakinra &#038; Tocilizumab-  associated with improved clinical outcomes"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.11.20192401v1<\/p>\n<p class=\"\">84 consecutive patients who received either treatment (51 in the Anakinra\/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar in both groups. There was no significant difference regarding to death (21.6% vs 15.2%, p 0.464), intubation (15.7% vs 24.2%, p 0.329), ICU need (57.1% vs 48.5%, p 0.475) or length of stay (13+9.6 vs 14.9+11.6, p 0.512) in the Anakinra\/IVIG and Tocilizumab, respectively. Additionally, the rate of improvement in ROX index, NEWS score and inflammatory markers was similar in both groups at days 7 and 14. Furthermore, there was no difference in the incidence of superinfection in both groups. Treating COVID-19 pneumonia associated with cytokine storm features with either subcutaneous Anakinra\/IVIG or intravenous Tocilizumab is associated with improved clinical outcomes in most subjects. The choice of treatment does not appear to affect morbidity or mortality.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.11.20192401v1 84 consecutive patients who received either treatment (51 in the Anakinra\/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/13-sep-2020-anakinra-tocilizumab-associated-with-improved-clinical-outcomes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(13 Sep 2020) Anakinra &#038; Tocilizumab-  associated with improved clinical outcomes&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[56,4,18],"tags":[57,27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/537"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=537"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/537\/revisions"}],"predecessor-version":[{"id":538,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/537\/revisions\/538"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}